(Q52644831)

5 May 2018

title

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. (English)

1 reference

5 May 2018

32

Bernard Escudier

1 reference

5 May 2018

Frede Donskov

12

0 references

Alain Ravaud

object named as

Alain Ravaud

18

0 references

Marc-Oliver Grimm

19

object named as

Marc-Oliver Grimm

1 reference

5 May 2018

Howard Gurney

16

0 references

Toni K Choueiri

6

object named as

Toni K Choueiri

1 reference

5 May 2018

author name string

Robert J Motzer

1

1 reference

5 May 2018

Nizar M Tannir

2

1 reference

5 May 2018

David F McDermott

3

1 reference

5 May 2018

Osvaldo Arén Frontera

4

1 reference

5 May 2018

Bohuslav Melichar

5

1 reference

5 May 2018

Elizabeth R Plimack

7

1 reference

5 May 2018

Philippe Barthélémy

8

1 reference

5 May 2018

Camillo Porta

9

1 reference

5 May 2018

Saby George

10

1 reference

5 May 2018

Thomas Powles

11

1 reference

5 May 2018

Victoria Neiman

13

1 reference

5 May 2018

Christian K Kollmannsberger

14

1 reference

5 May 2018

Pamela Salman

15

1 reference

5 May 2018

Robert Hawkins

17

1 reference

5 May 2018

Sergio Bracarda

20

1 reference

5 May 2018

Carlos H Barrios

21

1 reference

5 May 2018

Yoshihiko Tomita

22

1 reference

5 May 2018

Daniel Castellano

23

1 reference

5 May 2018

Brian I Rini

24

1 reference

5 May 2018

Allen C Chen

25

1 reference

5 May 2018

Sabeen Mekan

26

1 reference

5 May 2018

M Brent McHenry

27

1 reference

5 May 2018

Megan Wind-Rotolo

28

1 reference

5 May 2018

Justin Doan

29

1 reference

5 May 2018

Padmanee Sharma

30

1 reference

5 May 2018

Hans J Hammers

31

1 reference

5 May 2018

CheckMate 214 Investigators

33

1 reference

5 May 2018

language of work or name

English

0 references

publication date

21 March 2018

1 reference

5 May 2018

The New England Journal of Medicine

number of pages

14

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

5 May 2018

volume

378

1 reference

5 May 2018

issue

14

1 reference

5 May 2018

page(s)

1277-1290

1 reference

5 May 2018

Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5972549

Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

25 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5972549

Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.

25 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5972549

Systemic Therapy for Metastatic Renal-Cell Carcinoma

25 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5972549

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.

25 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5972549

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

25 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5972549

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

25 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5972549

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

25 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5972549

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

25 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5972549

Alternate sunitinib schedules in patients with metastatic renal cell carcinoma

25 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5972549

Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial

25 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5972549

Nivolumab in previously untreated melanoma without BRAF mutation

25 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5972549

Pazopanib versus sunitinib in metastatic renal-cell carcinoma

25 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5972549

Development and initial validation of the NCCN/FACT symptom index for advanced kidney cancer.

25 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5972549

Nivolumab plus ipilimumab in advanced melanoma

25 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5972549

External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study

25 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5972549

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

25 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5972549

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

25 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5972549

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study

25 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5972549

A Comparison of the Renal Cell Carcinoma-Symptom Index (RCC-SI) and the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI).

25 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5972549

Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma

25 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5972549

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

25 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5972549

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

25 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5972549

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

25 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5972549

Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis

25 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5972549

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

25 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5972549

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

25 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5972549

Karnofsky performance status revisited: reliability, validity, and guidelines

25 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/29562145

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1056/NEJMOA1712126

1 reference

5 May 2018

PMC publication ID

5972549

0 references

1 reference

5 May 2018